Literature DB >> 20443680

Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.

Shahab Uddin1, Rong Bu, Maqbool Ahmed, Azhar R Hussain, Dahish Ajarim, Fouad Al-Dayel, Prashant Bavi, Khawla S Al-kuraya.   

Abstract

We investigated the role of the leptin receptor (Ob-R) and its relationship with PI3K/AKT activation in diffuse large B-cell lymphoma (DLBCL) clinical samples followed by in vitro studies using a panel of CRC cell lines. Leptin exerts its physiological action through its receptor Ob-R. Overexpression of Ob-R has been implicated in the pathogenesis of a variety of malignancies; however, its role in DLBCL has not been investigated. Using immunohistochemistry on a large cohort of DLBCL samples in a tissue microarray format, Ob-R immunostaining was detected in 86/216 (39.8%). Ob-R overexpression was associated with the catalytic subunit p110 of PI3K (p = 0.0283), activated AKT (p = 0.0003), and antiapoptotic marker XIAP (p = 0.0008) expression. In in vitro analysis using DLBCL cell lines, our data showed that leptin stimulated cell proliferation and inhibited apoptosis via activation of the PI3K/AKT signaling pathway. Pretreatment of DLBCL cells with Ob-R specific small interference RNA or inactivation of PI3K/AKT activity by LY294002 abolished these responses. Altogether, these data suggest that leptin plays a critical role in DLBCL pathogesis through the P13K/AKT pathway via Ob-R.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20443680     DOI: 10.3109/10428191003802365

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  19 in total

1.  Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.

Authors:  Yihui Ma; Pengyu Zhang; Yi Gao; Huijie Fan; Mingzhi Zhang; Jingjing Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 2.  Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells.

Authors:  Shanchun Guo; Mingli Liu; Guangdi Wang; Marta Torroella-Kouri; Ruben R Gonzalez-Perez
Journal:  Biochim Biophys Acta       Date:  2012-01-24

Review 3.  Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.

Authors:  Adam J Adler; Payal Mittal; Joseph M Ryan; Beiyan Zhou; Jeffrey S Wasser; Anthony T Vella
Journal:  Immunotherapy       Date:  2017-01       Impact factor: 4.196

Review 4.  Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy?

Authors:  Jennifer Totonchy; Ethel Cesarman
Journal:  Curr Opin Virol       Date:  2016-09-23       Impact factor: 7.090

Review 5.  Leptin and its receptor in hematologic malignancies.

Authors:  Tian-Jie Han; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

6.  Leptin induces epithelial-to-mesenchymal transition via activation of the ERK signaling pathway in lung cancer cells.

Authors:  Min Xu; Fa-Le Cao; Naiyi Li; Xin Gao; Xuejia Su; Xiaoling Jiang
Journal:  Oncol Lett       Date:  2018-07-30       Impact factor: 2.967

Review 7.  Role of leptin and its receptors in the pathogenesis of thyroid cancer.

Authors:  Shahab Uddin; Azhar R Hussain; Abdul K Siraj; Omar S Khan; Prashant P Bavi; Khawla S Al-Kuraya
Journal:  Int J Clin Exp Pathol       Date:  2011-10-03

8.  Leptin reverts pro-apoptotic and antiproliferative effects of α-linolenic acids in BCR-ABL positive leukemic cells: involvement of PI3K pathway.

Authors:  Aurore Beaulieu; Géraldine Poncin; Zakia Belaid-Choucair; Chantal Humblet; Gordana Bogdanovic; Georges Lognay; Jacques Boniver; Marie-Paule Defresne
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

9.  The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas.

Authors:  Pinelopi Argyriou; Panagiota Economopoulou; Sotirios Papageorgiou
Journal:  Adv Hematol       Date:  2011-06-16

10.  Leptin and cancer: Pathogenesis and modulation.

Authors:  Deep Dutta; Sujoy Ghosh; Kaushik Pandit; Pradip Mukhopadhyay; Subhankar Chowdhury
Journal:  Indian J Endocrinol Metab       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.